Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Indivior Pharmaceuticals, Inc.

NASDAQ: SUPN · Life Sciences · 7 alerts · CIK 1625297

Share price
$28.83Close, Nov 16
Market cap
$3.4B
Shares outstanding
118.04MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Indivior Pharmaceuticals, Inc. filings on SEC EDGAR ↗

9:11 AM ET 8-K
Loan & Debt

Supernus Debt Financing Update with U.S. Bank Trust Company, National Association

Supernus, Inc. announced an adjustment to the conversion rate for its 0.625% Convertible Senior Notes due 2031 following a previously declared special dividend. The conversion rate increased from 24.0033 to 30.9355 shares per $1,000 principal amount, resulting in a new conversion price of approximately $32.33 per share.

Counterparty
U.S. Bank Trust Company, National Association
9:28 AM ET 8-K
M&A Deal

Indivior Pharmaceuticals M&A Deal with Supernus Pharmaceuticals, Inc.

Indivior Pharmaceuticals completed its previously announced merger with Supernus Pharmaceuticals, with the combined entity renamed Supernus, Inc. (Nasdaq: SUPN). To fund a $1.0 billion special cash dividend to legacy Indivior stockholders, the company entered into a $650 million senior secured term loan facility with Citibank.

Counterparty
Supernus Pharmaceuticals, Inc.
7:01 AM ET 8-K
M&A Deal

Indivior Pharmaceuticals M&A Deal with Supernus Pharmaceuticals, Inc.

Indivior reported record Q3 2026 financial results while providing a status update on its pending all-stock merger of equals with Supernus Pharmaceuticals. The merger, which has received shareholder approval, is expected to close on November 2, 2026, with the combined company operating as Supernus, Inc. (ticker: SUPN).

Counterparty
Supernus Pharmaceuticals, Inc.

“In the third quarter, we delivered record SUBLOCADE net revenue and record adjusted EBITDA, reflecting the strength of our business and the disciplined execution of the Indivior Action Agenda. Upon the imminent closing of our merger with Supernus, we will have successfully completed all three phases of the Indivior Action Agenda.”

Joe Ciaffoni, Chief Executive Officer

“We achieved record financial performance in the third quarter, including SUBLOCADE net revenue growth of 22% year-over-year and adjusted EBITDA margin of 59%, up 2100 basis points year-over-year.”

Ryan Preblick, Chief Financial Officer
4:18 PM ET 8-K
M&A Deal

Indivior Pharmaceuticals M&A Deal Update

Stockholders of Indivior Pharmaceuticals, Inc. approved the issuance of common stock in connection with a previously announced merger agreement. The vote satisfies Nasdaq Rule 5635 requirements for the share issuance, marking a key step toward completing the acquisition.

7:15 AM ET 8-K
M&A Deal

Indivior Pharmaceuticals M&A Deal with Supernus Pharmaceuticals, Inc.

Indivior Pharmaceuticals, Inc. provided a status update on its pending merger with Supernus Pharmaceuticals, Inc., specifically addressing supplemental disclosures to the joint proxy statement/prospectus. The update follows demand letters and complaints from Supernus stockholders alleging disclosure deficiencies, which the company believes are meritless but is addressing to avoid litigation risk. The special meetings for stockholders of both companies to vote on the merger are scheduled for October 15, 2026.

Counterparty
Supernus Pharmaceuticals, Inc.
7:18 AM ET 8-K
Dividend

Indivior Pharmaceuticals Dividend

Indivior Pharmaceuticals declared a special cash dividend of $8.13 per share to be paid to stockholders of record as of October 30, 2026. The payment is strictly contingent upon the closing of Indivior's pending merger with Supernus Pharmaceuticals, which is expected to occur on or about November 2, 2026. Supernus stockholders will not receive this dividend for shares received as merger consideration.

Counterparty
Supernus Pharmaceuticals, Inc.
4:28 PM ET 8-K
Deal Termination

Indivior Pharmaceuticals Deal Termination with Reckitt Benckiser Healthcare Limited

Indivior UK Limited and Reckitt Benckiser Healthcare (UK) Limited entered into a Deed of Variation and Termination to accelerate the end of their Copacker Supply Agreement for SUBOXONE and SUBUTEX tablets to January 15, 2027. Indivior has identified a new supplier and will pay RB fixed or capped costs related to the early termination, including asset disposal and redundancy costs. The company stated the financial impact of the termination and the new supplier agreement is not expected to be material.

Counterparty
Reckitt Benckiser Healthcare (UK) Limited
Term
through Jan 15, 2027

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.